1. Home
  2. EQT vs BIIB Comparison

EQT vs BIIB Comparison

Compare EQT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EQT Corporation

EQT

EQT Corporation

HOLD

Current Price

$48.68

Market Cap

33.6B

Sector

Energy

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$198.96

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQT
BIIB
Founded
1925
1978
Country
United States
United States
Employees
1873
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.6B
27.3B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
EQT
BIIB
Price
$48.68
$198.96
Analyst Decision
Buy
Buy
Analyst Count
21
25
Target Price
$69.15
$206.83
AVG Volume (30 Days)
6.2M
1.1M
Earning Date
04-21-2026
04-29-2026
Dividend Yield
1.12%
N/A
EPS Growth
635.56
N/A
EPS
2.36
2.15
Revenue
$8,644,211,000.00
$9,890,600,000.00
Revenue This Year
$20.28
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.23
$92.50
Revenue Growth
63.92
2.22
52 Week Low
$48.47
$121.06
52 Week High
$68.24
$219.72

Technical Indicators

Market Signals
Indicator
EQT
BIIB
Relative Strength Index (RSI) 29.76 46.79
Support Level N/A $184.00
Resistance Level $57.62 $201.52
Average True Range (ATR) 1.23 6.72
MACD -0.09 -1.38
Stochastic Oscillator 12.21 18.70

Price Performance

Historical Comparison
EQT
BIIB

About EQT EQT Corporation

EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and its transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: